我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破OA

Brain cytoprotection therapy serves as an important adjunct to reperfusion therapy for acute ischemic stroke,yet it has long faced challenges in clinical translation.In recent years,research teams in China,guided by clinical needs,have made notable progress in this field.This article systematically reviews the progress of basic and clinical research on brain cytoprotection.Firstly,it elaborates on the core therapeutic targets,and the guiding role of the stroke treatment academic industry roundtable(STAIR)and the stroke preclinical assessment network(SPAN).Secondly,it highlights the breakthrough achievements in clinical research in China,including the research data and clinical application value of representative drugs such as edaravone dexborneol,minocycline,and loberamisal.Finally,it analyzes the current challenges faced in this field and looks forward to future development strategies,aiming to provide a reference for promoting the innovation and clinical translation of brain cytoprotection therapy for acute ischemic stroke.